SpicyIP

FEBRUARY 23, 2025

on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt. on 14 February, 2025 (Delhi HC) TThe plaintiff, a manufacturer of Ayurvedic and Unani medicines, filed a suit seeking a permanent injunction against the defendants for trademark and copyright infringement of its well-known ‘KUKA’ brand. Read the post for more.

Confidentiality 52

Confidentiality Trademark Copyright Infringement Music 52

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

LexBlog IP

FEBRUARY 23, 2024

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

Settlement 40

Settlement Marketing Marketing Licensing 40

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. Market Entry Date for Ustekinumab Biosimilar appeared first on Big Molecule Watch. Amgen secured a U.S.

Marketing 40

Marketing Marketing Settlement Licensing 40

LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

Invention 59

Invention Art Trademark Patent Application 59

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. MSMEs foster innovation by nurturing aspiring entrepreneurs, encouraging the development of innovative goods that enhance market competitiveness and fuel sustained growth.

Settlement 52

Settlement Intellectual Property Registration Designs 52

LexBlog IP

NOVEMBER 5, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Government Litigation 40

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. In addition, fewer new biosimilars entered the market this past year, with five biosimilar launches in 2020 as compared to seven in 2019. January 2021. off ASP and 23.7%

Settlement 52

Settlement Litigation Marketing Marketing 52

LexBlog IP

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Licensing Litigation 40

Technology & Marketing Law Blog

MARCH 19, 2025

The settlement says: subdivisions (a)(3), (a)(4)(A), and (a)(5) of California Business and Professions Code section 22677 violate the First Amendment of the United States Constitution facially and as applied to Plaintiff The state also must pay X $345,576 to cover its challenge costs. settlement filed Feb. Great job, California.

Social Media 59

Social Media Law Settlement Reporting 59

SpicyIP

FEBRUARY 10, 2025

Lodha TM battle Following disagreements over how a family settlement agreement is to be interpreted, the Lodha brothers are tangling over the Lodha trademark. Union Budget 2025-26: Whats in it for Innovation, Tech, Trade and Health? The FM Nirmala Sitharaman on February 1 presented the Union Budget 2025-26. amongst others.

Registering Trademarks 59

Registering Trademarks Trademark Copyright Business 59

SpicyIP

DECEMBER 31, 2024

Wishing everyone a prosperous and a healthy new year ahead and hoping that 2025 brings in spicier IP developments to the Indian IP regime, making it a more fair, balanced and effective one! Happy 2025! A) Top 10 IP Judgements/Orders (Topicality/Impact) 1. Novex Communications Pvt Ltd v. And with that we end our round-up for this year!

IP 105

IP Invention Patent Copyright 105